Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Posted by Mitch Edgeman on Feb 19th, 2025

Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 41,700 shares, a growth of 7.8% from the January 15th total of 38,700 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average daily trading volume, of 34,200 shares, the days-to-cover ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Evoke Pharma in a report on Sunday. They issued a “sell” rating for the company.

View Our Latest Research Report on EVOK

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC increased its position in Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) by 163.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 at the end of the most recent quarter.

Evoke Pharma Stock Performance

Shares of NASDAQ EVOK traded down $0.16 during midday trading on Tuesday, hitting $5.21. 13,877 shares of the company’s stock traded hands, compared to its average volume of 9,590. The stock has a market capitalization of $7.76 million, a price-to-earnings ratio of -0.47 and a beta of 0.16. The firm has a fifty day moving average of $4.65 and a 200 day moving average of $4.82. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $12.32.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.